Results 141 to 150 of about 28,682 (177)

Under ONIOM Layers: Analysis of BCR-ABL Enzyme Inhibitors Through Bond-Critical Points and Natural Orbitals. [PDF]

Molecules
Rocha KML, Nascimento ÉCM, Martins JBL.
europepmc   +1 more source

Study of the association between HDAC8, SIRT1, and P53 gene expression with drug resistance in chronic myeloid leukemia patients. [PDF]

BMC Cancer
Mansouri R, Heydarpour F, Yari K, Naseroleslami M, Payandeh M.   +4 more
europepmc   +1 more source

Predictors of Response to Imatinib Therapy and Long-Term Outcomes in Paediatric and Adolescent Patients With Chronic Myeloid Leukaemia. [PDF]

Cancer Rep (Hoboken)
Saha S, Yadav S, Singh MK, Rahman K, Chandra D, Gupta R, Kashyap R.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population

Annals of Hematology, 2012
Cytogenetic analyses of chronic myelogenous leukemia (CML) have been performed previously in a large number of reports, but systematical research based on large sample sizes from the Chinese population is seldom available. In this study, we analyzed the cytogenetic profiles of 1,863 Philadelphia (Ph)/BCR-ABL-positive CML patients from a research center
Qi-tian Mu, Qiu-ling Ma, Yungui Wang, Zhi-mei Chen, X. Tong, Fei-fei Chen, Ying Lu, Jie Jin   +7 more
semanticscholar   +3 more sources

Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft.

Experimental Hematology, 2000
An important step in successful autografting of patients with chronic myelogenous leukemia is the delivery of a leukemia-free graft. We conducted this study to determine whether the cytogenetic response after autografting was correlated with the number of BCR ABL-positive cells present within the stem cell grafts.By BCR-ABL mRNA quantification, we ...
M. Corsetti, E. Lerma, A. Dejana, M. Cavaliere, O. Figari, F. Vassallo, M. Abate, S. Luchetti, G. Piaggio, C. Parodi, G. Li Pira, F. Manca, A. Carella   +12 more
semanticscholar   +3 more sources

Presence of re-appearance of BCR-ABL-positive cells years after allogeneic bone marrow transplantation for chronic-phase chronic myelogenous leukemia in patients in hematological remission.

Acta Haematologica, 1994
Allogeneic bone marrow transplantation (BMT) is considered to be the only curative therapy for chronic myelogenous leukemia (CML). The cytogenetic marker of CML, the Philadelphia (Ph) chromosome, or the molecular alterations caused by the BCR-ABL gene fusion can be used to monitor the success of treatment.
L. Diekmann, D. Beelen, K. Quabeck, R. Becher, H. Schulte Holthausen, R. Bützler, U. Schaefer, B. Opalka   +7 more
semanticscholar   +3 more sources

Human medicines European public assessment report (EPAR): Tasigna, nilotinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 19/11/2007, Revision: 33, Status: Authorised

Case Medical Research, 2019

semanticscholar   +2 more sources

Human medicines European public assessment report (EPAR): Sprycel, dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 20/11/2006, Revision: 32, Status: Authorised

Case Medical Research, 2019

semanticscholar   +3 more sources

Transgenic Mouse Models of BCR/ABL-Positive Chronic Myelogenous Leukemia: A Review

Current Genomics, 2005
K. Inokuchi
semanticscholar   +2 more sources